Treatment of Moderate to Severe Refractory Crohn's Disease (NCT06721962)
A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease
🩺 Plain-English Summary (8th-Grade Level)
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Scottsdale, Arizona
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- Mayo Clinic Arizona — Scottsdale, Arizona
- University of California, Davis — Sacramento, California
- University of California, San Francisco — San Francisco, California
- University of Florida — Gainesville, Florida
- Northwestern — Chicago, Illinois
- University of Chicago — Chicago, Illinois
- University of Iowa — Iowa City, Iowa
- University of Louisville — Louisville, Kentucky
- University of Michigan — Ann Arbor, Michigan
- Mayo Clinic Rochester — Rochester, Minnesota
- Washington University in St. Louis — St Louis, Missouri
- Mount Sinai Health Systems — New York, New York
- Cleveland Clinic — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (858) 283-7879
Email: Tr1xClinicalTrials@Tr1x.bio
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohns Disease
- Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease — Dothan, Alabama
- Oral N-acetylglucosamine in Crohn's Disease — Baltimore, Maryland
- Pregnant Women With and Without Crohns Disease to Explore the Role of Plastics and Toxins in Intestinal Inflammation — New York, New York
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Atlanta, Georgia
- Protease Regulation and Impact of Sodium as Mechanisms of Inflammation in IBD — Hamilton, Ontario
- Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy — Rochester, Minnesota
Explore by condition: All Crohns Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.